You are here: Industry Insights > canakinumab

News List

Novartis’ canakinumab fails to meet primary endpoint in lung cancer trial pharmaceutical-technology
March 10, 2021
Novartis has reported that the Phase III CANOPY-2 study of canakinumab (ACZ885) in combination with the chemotherapy agent docetaxel failed to meet the primary endpoint of overall survival (OS) in patients with advanced or metastatic non-small cell ...
Canakinumab Study Fails to Meet Primary Endpoint americanpharmaceuticalreview
November 17, 2020
Novartis announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety of canakinumab in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome.
Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS) worldpharmanews
November 10, 2020
Novartis announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety of canakinumab in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome.
Novartis pulls EU filing for canakinumab pharmatimes
December 18, 2018
Novartis has pulled back its application to market canakinumab for the prevention of serious events such as stroke, myocardial infarction (MI) or death in patients who have had an MI in Europe.
Novartis pulls EU filing for canakinumab for the prevention of major cardiovascular events firstwordpharma
December 17, 2018
The European Medicines Agency said Friday that Novartis withdrew a marketing application seeking approval of canakinumab for the prevention of serious events such as stroke, myocardial infarction (MI) or death in patients who have had an MI.